Suimeikai (Triumeq) is a AIDS compound preparation developed by GlaxoSmithKline, which contains three antiretroviral drugs: Dotiravir, Abacavir and Lamivudine. The drug has been approved for marketing in multiple countries around the world, and its marketing situation in the Chinese market is as follows.

1. Domestic listing situation

(1) Listing status: Suimeikai has been officially listed in China.

(2) Approval time: Obtained approval from the China National Medical Products Administration in 2016.

2. Composition of drugs

(1) Duotelamivir: integrase inhibitor, 50mg.

(2) Abacavir: nucleoside reverse transcriptase inhibitor, 600mg.

(3) Lamivudine: nucleoside reverse transcriptase inhibitor, 300mg.

3 Indications

(1) Suitable for the treatment of HIV-1 infected individuals aged 12 and above, as well as adults.

(2) It should be used under the guidance of a professional physician.

4 Medication precautions

(1) HLA-B * 5701 gene testing is required before use.

(2) Adverse reactions such as headache and nausea may occur.

(3) Strictly follow the doctor's advice and take medication on time.